<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03677960</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-1968-202</org_study_id>
    <nct_id>NCT03677960</nct_id>
  </id_info>
  <brief_title>Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection</brief_title>
  <official_title>Open-Label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of Topical Abi-1968 In Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antiva Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antiva Biosciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal
      precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Pre-Clinical Toxicology Findings
  </why_stopped>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL</measure>
    <time_frame>MAD portion is 84 days</time_frame>
    <description>Number of participants with Adverse Events related to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.</measure>
    <time_frame>MAD portion is 84 days</time_frame>
    <description>Plasma concentrations of ABI-1968 over time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Histopathology of areas with biopsy-proven disease following multiple doses of ABI-1968 Topical Cream.</measure>
    <time_frame>MAD portion is 84 days</time_frame>
    <description>Number of subjects with complete and or partial regression of aHSIL by High Resolution Anoscopy (HRA) and histopathology</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>HSIL, High-Grade Squamous Intraepithelial Lesions</condition>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>HIV Infection</condition>
  <condition>Anal Cancer</condition>
  <condition>Anus Neoplasm</condition>
  <arm_group>
    <arm_group_label>Dose 1 - Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 - Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 - Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple Doses of Topical ABI-1968 cream applied by the Investigator in the clinic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical ABI-1968 cream</intervention_name>
    <description>Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29</description>
    <arm_group_label>Dose 1 - Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Dose 2 - Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Dose 3 - Multiple Ascending Dose(MAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Female or male subjects, at least 27 years old.

          2. Confirmed diagnosis of intra-anal HSIL at least 3 months prior to screening and
             confirmed by histopathology (with p16 positive staining)

          3. Intra-anal HSIL are visible and evaluable by HRA at the time of screening, and no
             lesion(s) is suspicious for invasive cancer.

          4. For HIV-positive subjects, CD4 count must be at least 200/mm3 with undetectable (&lt;50
             copies/mL) viral load within the 3 months prior to enrollment. Subjects must be on a
             stable regimen of antiretroviral drugs for the 3 months prior to enrollment.

        Exclusion Criteria:

          1. Women who are pregnant, plan to become pregnant in the next 3 months, or lactating
             females.

          2. Received topical treatment or ablative procedures for aHSIL in the 6 months prior to
             enrolment.

          3. History of cancer involving the anogenital region, or history of other cancers that
             have not been fully resolved and free of symptoms in the past 5 years

          4. History of genital herpes with &gt; 3 outbreaks per year.

          5. Plan to have excision or ablation of the lesion(s) within 3 months of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>27 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Darlinghurst</city>
        <state>Sydney</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>September 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2018</study_first_posted>
  <last_update_submitted>July 23, 2019</last_update_submitted>
  <last_update_submitted_qc>July 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

